More recently, it is generally accepted that data can be recorded in DNA sequences. Since this is realized by nature, why not take advantage of this for the benefit of the technological development of man? Also, the study of the mechanisms of DNA synthesis promises to lead to the emergence of individual medicine at the level of personal gene correction. The only problem is that the synthesis of long, clean and stable DNA strands is a complex process using toxic chemical compounds. A breakthrough can be the so-called enzymatic synthesis of DNA (enzymatic DNA synthesis), when enzymes are used to create the desired sequences, rather than "harsh" chemistry.
Among other companies and research laboratories, enzymatic DNA synthesis is being developed by the rather young Molecular Assemblies. It was created in 2013, but behind it is the 30-year-old experience of the profile scientists who formed the Molecular Assemblies. It is believed that Molecular Assemblies was the first to propose a commercial method for a relatively simple method for synthesizing long strands of DNA. In light of the interest in genome modifications and the need for new methods of recording information, this could not fail to attract investors. It is reported that the other day in the first collection of investments of series A, the company was able to attract 12.2 million funds for development.
Molecular Assemblies’s long-chain DNA synthesis method uses aqueous solutions and non-hazardous chemicals. The technology also features simple processing of chains after synthesis for extraction from solutions and further work with them. After that, DNA strands can be used for medical needs (cell CAR-T therapy and CRISPR gene editing), for modification of agricultural products, for industry and for studying data recording technologies at the molecular level.